Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Share-based Compensation (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Share-based Compensation over the past 16 years, most recently at $1.8 million for Q2 2025.

  • Quarterly results put Share-based Compensation at $1.8 million for Q2 2025, up 13.58% from a year ago — trailing twelve months through May 2025 was $10.2 million (up 63.81% YoY), and the annual figure for FY2025 was $10.2 million, up 63.81%.
  • Share-based Compensation for Q2 2025 was $1.8 million at Lifecore Biomedical, Inc. \De\, down from $2.6 million in the prior quarter.
  • Over the last five years, Share-based Compensation for LFCR hit a ceiling of $3.4 million in Q4 2024 and a floor of $620000.0 in Q3 2021.
  • Median Share-based Compensation over the past 5 years was $1.3 million (2022), compared with a mean of $1.4 million.
  • Biggest five-year swings in Share-based Compensation: surged 356.54% in 2021 and later crashed 75.93% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Share-based Compensation stood at $686000.0 in 2021, then soared by 61.52% to $1.1 million in 2022, then surged by 42.33% to $1.6 million in 2023, then soared by 113.82% to $3.4 million in 2024, then crashed by 46.17% to $1.8 million in 2025.
  • The last three reported values for Share-based Compensation were $1.8 million (Q2 2025), $2.6 million (Q1 2025), and $3.4 million (Q4 2024) per Business Quant data.